BOCA RATON, Fla., May 12, 2016 /PRNewswire/ -- IM HealthScience® (IMH), innovators of non-prescription IBgard® for the management of irritable bowel syndrome (IBS), announced today the planned retirement of Ellen Geisel, President of IM HealthScience®, who will be leaving the company in March 2017. Dave Swenson, Vice President of Marketing and Operations, will assume the role of President upon Ms. Geisel's retirement.
"Dave has played a critical role in the successful commercialization of our first product, IBgard®," said Ms. Geisel. "I am confident that under Dave's leadership the company will continue to grow rapidly through the continued strong growth of IBgard® and the launch of additional, innovative medical food products in the pipeline. You could not find a better, more experienced commercial executive to assume my responsibilities," she added.
Mr. Swenson joined IM HealthScience® in August 2015. Prior to joining the company, he was Managing Director of DOS & Associates. At DOS, his practice focused primarily on start-ups and in bringing healthcare innovations to the consumer marketplace. Prior to this role, he was General Manager at Alaven Consumer Healthcare where he formed a consumer healthcare division with specialty products in personal hygiene and gastroenterology. Mr. Swenson spent 16 years at Wyeth Consumer HealthCare in commercial positions where he worked on over 30 healthcare brands, including Advil and Centrum Vitamins.
"I am grateful to Ellen for her mentorship," said Mr. Swenson. "I also am grateful to her for being our leader in successfully launching the company and our lead product, IBgard®, and her legacy will be strong and deep. I am both humbled and honored to be chosen for this position. I look forward to working with my IMH colleagues to commercialize our exciting pipeline of innovative medical foods for the management of various gastrointestinal disorders."
About IM HealthScience®
IM HealthScience® (IMH) is a privately held company based in Boca Raton, Florida, that developed IBgard®. It was founded in 2010 by a team of highly experienced pharmaceutical research and development and management executives. The company is dedicated to developing products to address gastrointestinal issues where there is a high unmet need, including Irritable Bowel Syndrome (IBS), Functional Dyspepsia, Ulcerative Colitis, and Crohn's Disease. The IM HealthScience® advantage comes from developing products based on its patented, targeted- delivery technologies called Site Specific Targeting (SST®). For more information, visit www.IBgard.com to learn more about IBgard®.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/im-healthscience-imh-announces-succession-plan-300267399.html
SOURCE IM HealthScience